hAM15-52-analoger med forbedret amylinreceptor (hAMY3R)-potens

The present invention relates to hAM15-52 analogues with improved amylin receptor (hAMY3R) potency (hAMY3R-EC50≤250 pM) and which are largely based on the sequence of the human adrenomedullin fragment hAM15-52. The invention further relates to hAM15-52 analogues that are selective amylin receptor (h...

Full description

Saved in:
Bibliographic Details
Main Authors LUNDH, Morten, VRANG, Niels, MAGOTTI, Paola, NIELSEN, Jens, Christian, Frøslev, PEDERSEN, Søren, Ljungberg, BALLARÍN-GONZÁLES, Borja, RIGBOLT, Kristoffer, Tobias, Gustav, BECH, Esben, Matzen
Format Patent
LanguageDanish
Published 10.07.2023
Subjects
CHEMISTRY
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
METALLURGY
ORGANIC CHEMISTRY
PEPTIDES
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
Online AccessGet full text

Cover

More Information
Summary:The present invention relates to hAM15-52 analogues with improved amylin receptor (hAMY3R) potency (hAMY3R-EC50≤250 pM) and which are largely based on the sequence of the human adrenomedullin fragment hAM15-52. The invention further relates to hAM15-52 analogues that are selective amylin receptor (hAMY3R) agonists (hAMY3R-EC50≤250 pM and an hAM1R-EC50≥25 nM) and which are largely based on the sequence of the human adrenomedullin fragment hAM15-52. The hAM15-52 analogues according to the invention maintain the good physical stability of hAM15-52. The invention further relates to pharmaceutical compositions comprising such polypeptides and their use in the treatment of a medical condition such as obesity, NASH and/or diabetes.
Bibliography:Application Number: DK20210782735T